(Bloomberg) — AstraZeneca Plc fell from a record high in New York trading after data for the company’s Covid-19 vaccine candidate, though promising, fueled concerns about whether it can match competitors.Bernstein analysts led by Ronny Gal said the vaccine, developed in partnership with the University of Oxford, showed early positive data, but the benefits didn’t appear to match the bar set by programs from Pfizer Inc. and BioNtech SE, as well as Moderna Inc.“In the competitive context they fail to impress,” Gal wrote.Exacerbating concerns, the Lancet medical journal publication came just an hour after Pfizer and BioNtech had announced early …read more
Source:: Yahoo Finance
